![Prakash Raman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Prakash Raman
Director/Board Member at BLACK DIAMOND THERAPEUTICS, INC.
Net worth: 10 999 $ as of 2024-05-30
Profile
Prakash Raman is currently the Chief Executive Officer at Indupro and an Independent Director at Black Diamond Therapeutics, Inc. He is also a Director at NAYA Biosciences, Inc. Previously, he served as the Co-Chief Executive Officer & Director at KSQ Therapeutics, Inc. and as the President, Chief Executive Officer & Director at Ribon Therapeutics, Inc. Dr. Raman was also the VP & Global Head-NIBR Business Development at Novartis Institutes for Biomedical Research, Inc. He started his career as the Head-Project Management at AstraZeneca PLC.
Dr. Raman holds a doctorate degree from the University of Wisconsin and an undergraduate degree from the Indian Institute of Technology Bombay.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-06-20 | 2,301 ( 0.00% ) | 10 999 $ | 2024-05-30 |
Prakash Raman active positions
Companies | Position | Start |
---|---|---|
BLACK DIAMOND THERAPEUTICS, INC. | Director/Board Member | 2024-04-09 |
Indupro | Chief Executive Officer | 2024-06-12 |
Former positions of Prakash Raman
Companies | Position | End |
---|---|---|
ASTRAZENECA PLC | Corporate Officer/Principal | 2012-10-31 |
KSQ Therapeutics, Inc.
![]() KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Ribon Therapeutics, Inc.
![]() Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Chief Executive Officer | - |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Prakash Raman
University of Wisconsin | Doctorate Degree |
Indian Institute of Technology Bombay | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
Private companies | 4 |
---|---|
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Ribon Therapeutics, Inc.
![]() Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Health Technology |
KSQ Therapeutics, Inc.
![]() KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Health Technology |
Indupro |
- Stock Market
- Insiders
- Prakash Raman